Erytech Pharma Sa Stock Fundamentals
| ERYPDelisted Stock | USD 0.78 0.04 4.88% |
Erytech Pharma SA fundamentals help investors to digest information that contributes to Erytech Pharma's financial success or failures. It also enables traders to predict the movement of Erytech Stock. The fundamental analysis module provides a way to measure Erytech Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Erytech Pharma stock.
Erytech |
Erytech Pharma SA Company Operating Margin Analysis
Erytech Pharma's Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current Erytech Pharma Operating Margin | (4.08) % |
Most of Erytech Pharma's fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Erytech Pharma SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
CompetitionBased on the recorded statements, Erytech Pharma SA has an Operating Margin of -4.0841%. This is 88.36% lower than that of the Biotechnology sector and 96.36% lower than that of the Health Care industry. The operating margin for all United States stocks is 25.88% lower than that of the firm.
Erytech Pharma SA Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Erytech Pharma's current stock value. Our valuation model uses many indicators to compare Erytech Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Erytech Pharma competition to find correlations between indicators driving Erytech Pharma's intrinsic value. More Info.Erytech Pharma SA is rated # 2 in return on equity category among its peers. It is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Erytech Pharma by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Erytech Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Erytech Pharma's direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Erytech Pharma could also be used in its relative valuation, which is a method of valuing Erytech Pharma by comparing valuation metrics of similar companies.Erytech Pharma is currently under evaluation in operating margin category among its peers.
Erytech Fundamentals
| Return On Equity | -0.0098 | |||
| Return On Asset | -0.3 | |||
| Profit Margin | (0.03) % | |||
| Operating Margin | (4.08) % | |||
| Current Valuation | 211.16 K | |||
| Shares Outstanding | 34.12 M | |||
| Shares Owned By Institutions | 7.65 % | |||
| Number Of Shares Shorted | 17.79 K | |||
| Price To Earning | (5.88) X | |||
| Price To Book | 0.65 X | |||
| Price To Sales | 7.58 X | |||
| Gross Profit | 4.18 M | |||
| EBITDA | (22.69 M) | |||
| Net Income | (228 K) | |||
| Cash And Equivalents | 54.05 M | |||
| Cash Per Share | 1.74 X | |||
| Total Debt | 13.57 M | |||
| Debt To Equity | 1.00 % | |||
| Current Ratio | 2.25 X | |||
| Book Value Per Share | 0.76 X | |||
| Cash Flow From Operations | (31.76 M) | |||
| Short Ratio | 0.10 X | |||
| Earnings Per Share | (0.01) X | |||
| Target Price | 2.96 | |||
| Number Of Employees | 49 | |||
| Beta | 2.13 | |||
| Market Capitalization | 29.57 M | |||
| Total Asset | 45.81 M | |||
| Retained Earnings | (228 K) | |||
| Working Capital | 30.96 M | |||
| Current Asset | 94.53 M | |||
| Current Liabilities | 9.8 M | |||
| Z Score | 0.48 | |||
| Net Asset | 45.81 M |
About Erytech Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Erytech Pharma SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Erytech Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Erytech Pharma SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. The company was incorporated in 2004 and is headquartered in Lyon, France. Erytech Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 149 people.
Pair Trading with Erytech Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Erytech Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Erytech Pharma will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Erytech Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Erytech Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Erytech Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Erytech Pharma SA to buy it.
The correlation of Erytech Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Erytech Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Erytech Pharma SA moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Erytech Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Erytech Stock
If you are still planning to invest in Erytech Pharma SA check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Erytech Pharma's history and understand the potential risks before investing.
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges |